Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis
Table 6
Prognostic significance of anti-MX1 autoantibodies in IPF adjusted by parameters at the diagnosis of IPF.
Parameters
Univariate analysis
Adjusted by Cox analysis using parameters selected in Table 3
Adjusted by Cox analysis using GAP stage (I, II, III)
HR
95% CI
value
HR
95% CI
value
HR
95% CI
value
Anti-MX1 IgG Ab
27.21
0.339–2181
0.140
0.317
0.001–68.94
0.676
0.566
0.004–79.27
0.822
Anti-MX1 IgG Ab >0.237
1.707
0.804–3.620
0.164
0.845
0.364–1.903
0.696
0.952
0.465–2.257
0.952
Anti-MX1 IgA Ab
4.243
0.417–43.19
0.222
498.3
2.915–85200
0.018
306.4
1.744–53826
0.030
Anti-MX1 IgA Ab >0.312
7.250
1.997–26.319
0.003
7.602
2.013–28.70
0.003
5.552
1.488–20.717
0.011
Anti-MX1 IgM Ab
0.466
0.002–107.6
0.783
1.330
0.002–1017
0.933
2.231
0.006–800.5
0.789
Anti-MX1 IgM Ab >0.450
NA
NA
NA
MX1, myxovirus resistance protein-1; Ab, autoantibody; IPF, idiopathic pulmonary fibrosis; GAP stage, gender, age, and physiology stage; HR, hazard ratio; CI, confidence interval; Ig, immunoglobulin. Prognostic significance of each anti-MX1 autoantibodies, definite titer, or positivity more than cutoff values, was evaluated by univariate Cox proportional hazard regression analysis and HR adjusted by GAP stage was also shown.
